Protein / target
Baculoviral IAP repeat-containing protein 2
Protein at a glance
Biological role
Ubiquitin-protein transferase
Strongest disease association
Pre-Eclampsia
Therapeutic position
Clinically advancing target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis.
View complete UniProt function annotationHide complete annotation
Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling, and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions: acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, TRAF2, DIABLO/SMAC, MAP3K14/NIK, MAP3K5/ASK1, IKBKG/NEMO, IKBKE and MXD1/MAD1. Can also function as an E3 ubiquitin-protein ligase of the NEDD8 conjugation pathway, targeting effector caspases for neddylation and inactivation. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8. Can stimulate the transcriptional activity of E2F1. Plays a role in the modulation of the cell cycle
Subcellular location
Domains and Gene Ontology detail (52)Hide
Domains & features
Gene Ontology
- CCD40 receptor complex
- Ccytoplasm
- Ccytoplasmic side of plasma membrane
- Ccytosol
- Cnucleoplasm
- Cnucleus
- Cplasma membrane
- CXY body
- Fcysteine-type endopeptidase inhibitor activity involved in apoptotic process
- FFBXO family protein binding
- Fidentical protein binding
- Fprotein-containing complex binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·regulation of cell population proliferation
Apoptosis & cell death
- ·Multi-functional protein which regulates not only caspases and apoptosis, but also modul…
- ·cysteine-type endopeptidase inhibitor activity involved in apoptotic process
- ·negative regulation of apoptotic process
- ·regulation of apoptotic process
Transcriptional regulation
- ·Multi-functional protein which regulates not only caspases and apoptosis, but also modul…
- ·transcription coactivator activity
- ·DNA-templated transcription
Immune signalling
- ·inflammatory response
- ·regulation of inflammatory response
- ·regulation of innate immune response
Metabolic enzyme activity
- ·transferase activity
- ·ubiquitin-protein transferase activity
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
cIAP1/cIAP2 inhibitor
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene BIRC2
Gene-level evidence surfaced through the gene BIRC2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
1 compounds recorded · 1 in clinical development
View all recorded compounds (1)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Protein degraders — Emerging
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (8)Hide
ClinicalTrials.gov via the drug-target graph.